A New Era Of Post-Plea Compliance Obligations

Law360, New York (September 24, 2013, 9:56 AM ET) -- An important trend is emerging in pharmaceutical settlements with potential long-term ramifications for any company in the government’s crosshairs. Now, even if a company pays millions or even billions of dollars to secure a resolution and bring closure to a costly multiyear U.S. Department of Justice investigation, it may nevertheless find itself in a long-term relationship with the DOJ that includes ongoing oversight and the risk of additional penalties. That is the new reality facing life sciences companies grappling with whistleblower-initiated government investigations.

The Justice Department...
To view the full article, register now.